[New drug approval: Nivolumab plus Ipilimumab/chemotherapy in esophageal squamous-cell carcinoma]

Bull Cancer. 2022 Oct;109(10):990-991. doi: 10.1016/j.bulcan.2022.05.011. Epub 2022 Aug 16.

[Article in French]

Authors

Céline Chalah¹, Cindy Neuzillet²

Affiliations

¹ Hôpital Saint-Antoine, service de gastro-entérologie, 184, Rue du Faubourg Saint-Antoine, 75012 Paris, France. Electronic address: Celine.chalah@aphp.fr.
² Institut Curie - Site de Saint Cloud, 35, Rue Dailly, 92210 Saint-Cloud, France.

PMID: 35985867
DOI: 10.1016/j.bulcan.2022.05.011

No abstract available

Keywords: Anti-CTLA4; Anti-CTLA4, Cancer de l’œsophage; Anti-PD1; Esophageal cancer; Immune therapy; Immunothérapie.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Drug Approval
Humans
Ipilimumab / therapeutic use
Nivolumab* / therapeutic use

Substances

Ipilimumab
Nivolumab